Previous 10 | Next 10 |
Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing All Six Target Clinical Sites are on Track to be Fully Opened by Year End ASHBURN, Va., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Co...
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Conference Call November 10, 2022, 10:00 AM ET Company Participants Gordon Dunn - CFO Michael Myers - CEO Conference Call Participants Aydin Huseynov - Ladenburg Thalmann James Molloy - Alliance Glob...
Quoin Pharmaceuticals press release ( NASDAQ: QNRX ): Q3 Loss per ADS of -$0.94 beats by $0.41 . Ended Q3 with ~$15.2M in cash and marketable securities. Ongoing clinical study for QRX003 in Netherton Syndrome continues to progress, with a majority of clinical site...
Company completed a public offering for aggregate gross proceeds of $16.8 million Majority of clinical sites now open in clinical study to evaluate QRX003 for Netherton Syndrome Quoin announced plans to initiate second clinical trial to evaluate QRX003 in Netherton Syndr...
ASHBURN, Va., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today updated timing for its third quarter 2022...
ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its third quarter 2022 financial res...
Are These Penny Stocks To Buy Right Now Or Avoid Entirely? This article will discuss penny stocks to buy. Specifically, the “to buy” part is based on several Wall Street analysts. It’s also a continuation of our article 3 Penny Stocks With 1,000% Upside Potential ...
Quoin Pharmaceuticals ( NASDAQ: QNRX ) stock rose ~22% on Tuesday after the company said it was starting a second trial in patients with Netherton Syndrome (NS). NS is a rare genetic disorder characterized by scaling skin, hair issues, and increased susce...
ASHBURN, Va., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces that it is initiating a second clinical trial in Netherton Synd...
Penny stocks are some of the most volatile types of stocks out there. This article looks at a handful of cheap stocks to watch as the stock market crash continues. Why would anyone want to take on so much risk during times like these? The simple answer is capitalizing on volatility. The S&a...
News, Short Squeeze, Breakout and More Instantly...
Quoin Pharmaceuticals Ltd. Company Name:
QNRX Stock Symbol:
NASDAQ Market:
Quoin Pharmaceuticals Ltd. Website:
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has Been Engaged Plans for the Opening of Additional International Sites at an Advan...
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundat...
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery ...